Apellis Appoints Craig Wheeler to Board of Directors

Apellis Pharmaceuticals has appointed Craig Wheeler, an executive with over 30 years of biopharmaceutical leadership experience, to its Board of Directors, effective April 2025. Wheeler, founder and CEO of Headwaters Biotech Advisors and former CEO of Momenta Pharmaceuticals, is recognized for guiding companies through significant growth and successful acquisitions, notably Momenta's sale to Johnson & Johnson. He will also join the Audit Committee and receive equity-based compensation aligned with other non-employee directors. Company leaders expressed confidence that Wheeler’s expertise in commercialization, pipeline development, and immunology will help advance Apellis’s mission of delivering innovative therapies for unmet medical needs. Financial analysts note that his appointment may bolster investor confidence, support strategic growth initiatives, and enhance Apellis's competitive position, though no immediate strategic changes were announced. Apellis currently maintains strong liquidity and robust revenue growth despite ongoing profitability challenges and competitive pressures.